CanSino Biologics Inc.
CanSino Biologics Inc. (CASBF) Revenue
Annual & quarterly revenue history · segment & region breakdown
CASBF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCanSino Biologics Inc. trailing twelve-month (TTM) revenue is $1.11B, an increase of 25.12% year-over-year from $1.03B in FY2025.
Revenue trend
2025 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $1.03B | +$0.21B | +25.12% |
| 2024-12-31 | $0.82B | +$0.48B | +138.97% |
| 2023-12-31 | $0.35B | -$0.69B | -66.52% |
| 2022-12-31 | $1.03B | -$3.27B | -76.02% |
| 2021-12-31 | $4.30B | +$4.27B | +17174.82% |
| 2020-12-31 | $0.02B | +$0.02B | +990.05% |
| 2019-12-31 | $0.00B | +$0.00B | +101.71% |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $-0.00B | -$0.01B | -107.35% |
| 2016-12-31 | $0.01B | — | — |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare CASBF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income CanSino Biologics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
CanSino Biologics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CNY.
Data sourced from CanSino Biologics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CASBF revenue · 4 questionsCASBF's trailing twelve-month (TTM) revenue is $1.11B. That is an increase of 25.12% year-over-year from $1.03B in FY2025.
▸ Source: FMP · CanSino Biologics Inc. SEC filings · GAAP · CanSino Biologics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026